These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 24851861)
1. Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations. Sheridan GK; Dev KK Sci Rep; 2014 May; 4():5051. PubMed ID: 24851861 [TBL] [Abstract][Full Text] [Related]
2. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Chun J; Hartung HP Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941 [TBL] [Abstract][Full Text] [Related]
4. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway. Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062 [TBL] [Abstract][Full Text] [Related]
5. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice. Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045 [TBL] [Abstract][Full Text] [Related]
6. Morpholino Analogues of Fingolimod as Novel and Selective S1P Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717 [TBL] [Abstract][Full Text] [Related]
7. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494 [TBL] [Abstract][Full Text] [Related]
8. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Brinkmann V Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729 [TBL] [Abstract][Full Text] [Related]
9. Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions. Obinata H; Gutkind S; Stitham J; Okuno T; Yokomizo T; Hwa J; Hla T J Lipid Res; 2014 Dec; 55(12):2665-75. PubMed ID: 25293589 [TBL] [Abstract][Full Text] [Related]
10. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis. de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Al-Izki S; Pryce G; Jackson SJ; Giovannoni G; Baker D Mult Scler; 2011 Aug; 17(8):939-48. PubMed ID: 21459808 [TBL] [Abstract][Full Text] [Related]
13. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831 [TBL] [Abstract][Full Text] [Related]
14. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187 [TBL] [Abstract][Full Text] [Related]
15. Roles for lysophospholipid S1P receptors in multiple sclerosis. Noguchi K; Chun J Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571 [TBL] [Abstract][Full Text] [Related]
16. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Baumruker T; Billich A; Brinkmann V Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523 [TBL] [Abstract][Full Text] [Related]
17. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291 [TBL] [Abstract][Full Text] [Related]